Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molecular Analysis for Combination Therapy Choice (ComboMATCH)
NCT05564377Phase 2
Key facts
- Status
- Recruiting
- Start
- Apr 2023
- Primary completion
- Jul 2030
- Countries
- 2
- Sponsor
- National Cancer Institute
- Conditions
- solid tumor
01
Overview
Phase 2, randomised, open-label trial of alpelisib, binimetinib, fluorouracil, fulvestrant, ipatasertib and 10 more in solid tumor (20 arms), sponsored by National Cancer Institute. Primary endpoints: Accrual of patients to ComboMATCH treatment trials at 8 years, Assignment of patients to ComboMATCH treatment trials at 8 years and 1 more. Started Apr 2023; status: recruiting.
02
Design
20 arms- Study design
- RandomizedOpen-label
EAY191-N4 Arm I
selumetinib + olaparib
EAY191-N4 Arm II
selumetinib
EAY191-N2 Cohort I Arm I
fulvestrant + binimetinib
EAY191-N2 Cohort I Arm II
fulvestrant
EAY191-N2 Cohort II
fulvestrant + binimetinib
EAY191-E4
nilotinib + paclitaxel
14 more in the full profile.
03
Who it enrols
Patients with locally advanced or advanced solid tumors who have progressed on at least one line of standard systemic therapy or have no standard treatment, with measurable disease and available sequencing results from an NCI credentialed Designated Laboratory.
04
Endpoints
Primary
Accrual of patients to ComboMATCH treatment trials
Assignment of patients to ComboMATCH treatment trials
Enrollment rates to ComboMATCH treatment trials
Secondary
Rate of positive outcomes within the treatment trial defined cohorts
Beyond the preview
Go deeper on NCT05564377.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05564377.